NCT07065331CompletedPhase 1
A Study of Inhaled AZD8630 in Adolescents With Asthma
A Phase I, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Inhaled AZD8630 in Adolescents With Asthma
Source: ClinicalTrials.gov · Last updated 14 Oct 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, tolerability, and immunogenicity of single inhaled dose of AZD8630 administered in adolescent participants with asthma as well as the safety and performance of the dry powder inhaler.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 11 Jun 2025
- Start date
- 11 Jun 2025
- Primary completion date
- 19 Sept 2025
- Lead sponsor
- AstraZeneca
- Diseases
- Asthma
- NCT number
- NCT07065331
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 10
- From 11 Jun 2025 to the primary completion date, 19 Sept 2025
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Oral immunotherapy, including stable maintenance dose allergen-specific oral immunotherapy.
Other illness
- History of any clinically important disease or disorder.
- History of any chronic respiratory disorders (except asthma).
- Completed treatment for respiratory infection with antibiotics within 4 weeks of Screening.
- History of acquired or inherited immunodeficiency disorders.
Other
- Acute exacerbation of asthma within 4 weeks of Screening.
- Life -threatening asthma.
Who the study is looking for
- Physician prescribed daily use of asthma medication.
- Pre-bronchodilator Forced expiratory volume in one second (FEV1) ≥ 50% of the predicted normal value.
- Asthma control questionnaire-5 (ACQ-5) \< 1.5 at Screening and Study Day 1.
Age in the registry: 12 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Research Site Coordinator of this site? Confirm its status | Bakersfield | United States | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Boerne | United States | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Lafayette | United States | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Miami Lakes | United States | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Oklahoma City | United States | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Raleigh | United States | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Salt Lake City | United States | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Spartanburg | United States | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Toledo | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.